Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance
Clinical trial NCT04316351 · UNKNOWN
Trial details
- NCT number
- NCT04316351
- Sponsor
- Guangzhou Institute of Respiratory Disease
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-01
- Primary completion
- 2022-04-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.